Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new study found that Medicaid expansion didn't significantly reduce inflammatory bowel disease (IBD) mortality over 26 years. But researchers caution against reading too much into it — mortality is just one piece of the IBD puzzle. Better specialist access and fewer insurance hurdles may be what's really needed to improve patient outcomes.
A study presented at the ACG Annual Scientific Meeting found that Medicaid expansion did not significantly reduce IBD-related mortality over a 26-year period. Researchers compared age-adjusted IBD death rates in states that expanded Medicaid by January 2016 versus those that hadn't through 2024 — and while expansion states saw a smaller rise in mortality, the difference wasn't statistically significant.
But the lead researcher, Dr. Daniyal Raza of LSU Health Shreveport, is urging caution before drawing sweeping conclusions. Mortality, he notes, captures only one dimension of life with IBD — it doesn't reflect symptom control, hospitalizations, treatment consistency, or quality of life. Having insurance, he points out, doesn't automatically mean patients can access effective care.
By the Numbers:
Why it matters: This study is a reminder that insurance coverage is necessary but not sufficient. For GI providers, the real question is: what barriers — prior authorizations, drug costs, follow-up gaps — are still blocking patients from getting effective care even after they're covered?
